Literature DB >> 18394553

Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells.

Peggy Kirstetter1, Mikkel B Schuster, Oksana Bereshchenko, Susan Moore, Heidi Dvinge, Elke Kurz, Kim Theilgaard-Mönch, Robert Månsson, Thomas A Pedersen, Thomas Pabst, Evelin Schrock, Bo T Porse, Sten Eirik W Jacobsen, Paul Bertone, Daniel G Tenen, Claus Nerlov.   

Abstract

Mutations in the CEBPA gene are present in 7%-10% of human patients with acute myeloid leukemia (AML). However, no genetic models exist that demonstrate their etiological relevance. To mimic the most common mutations affecting CEBPA-that is, those leading to loss of the 42 kDa C/EBPalpha isoform (p42) while retaining the 30kDa isoform (p30)-we modified the mouse Cebpa locus to express only p30. p30 supported the formation of granulocyte-macrophage progenitors. However, p42 was required for control of myeloid progenitor proliferation, and p42-deficient mice developed AML with complete penetrance. p42-deficient leukemia could be transferred by a Mac1+c-Kit+ population that gave rise only to myeloid cells in recipient mice. Expression profiling of this population against normal Mac1+c-Kit+ progenitors revealed a signature shared with MLL-AF9-transformed AML.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18394553     DOI: 10.1016/j.ccr.2008.02.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  118 in total

1.  Expression of the transcriptional repressor Gfi-1 is regulated by C/EBP{alpha} and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells.

Authors:  Maria Rosa Lidonnici; Alessandra Audia; Angela Rachele Soliera; Marco Prisco; Giovanna Ferrari-Amorotti; Todd Waldron; Nick Donato; Ying Zhang; Robert V Martinez; Tessa L Holyoake; Bruno Calabretta
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.

Authors:  Alan H Shih; Yanwen Jiang; Cem Meydan; Kaitlyn Shank; Suveg Pandey; Laura Barreyro; Ileana Antony-Debre; Agnes Viale; Nicholas Socci; Yongming Sun; Alexander Robertson; Magali Cavatore; Elisa de Stanchina; Todd Hricik; Franck Rapaport; Brittany Woods; Chen Wei; Megan Hatlen; Muhamed Baljevic; Stephen D Nimer; Martin Tallman; Elisabeth Paietta; Luisa Cimmino; Iannis Aifantis; Ulrich Steidl; Chris Mason; Ari Melnick; Ross L Levine
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

Review 3.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 4.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

5.  Repression of transcriptional activity of C/EBPalpha by E2F-dimerization partner complexes.

Authors:  Katrin Zaragoza; Valérie Bégay; Anja Schuetz; Udo Heinemann; Achim Leutz
Journal:  Mol Cell Biol       Date:  2010-02-22       Impact factor: 4.272

Review 6.  C/EBPα deregulation as a paradigm for leukemogenesis.

Authors:  J A Pulikkan; D G Tenen; G Behre
Journal:  Leukemia       Date:  2017-07-19       Impact factor: 11.528

Review 7.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer.

Authors:  Steffen Koschmieder; Balazs Halmos; Elena Levantini; Daniel G Tenen
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

8.  Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.

Authors:  Elizabeth Heyes; Luisa Schmidt; Gabriele Manhart; Thomas Eder; Ludovica Proietti; Florian Grebien
Journal:  Leukemia       Date:  2021-02-23       Impact factor: 11.528

9.  HOX expression patterns identify a common signature for favorable AML.

Authors:  M Andreeff; V Ruvolo; S Gadgil; C Zeng; K Coombes; W Chen; S Kornblau; A E Barón; H A Drabkin
Journal:  Leukemia       Date:  2008-07-31       Impact factor: 11.528

Review 10.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.